The U.S. Food and Drug Administration has approved GlaxoSmithKline's 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...

The U.S. Food & Drug Administration (FDA) has granted approval for a novel and less invasive belimumab (Benlysta®) treatment for children with systemic lupus erythematosus (SLE) ages five years and ...

Several years of preliminary research results suggest chimeric antigen receptor (CAR) T-cell therapy could benefit pediatric patients with refractory systemic lupus erythematosus (SLE). When diagnosed ...

Please provide your email address to receive an email when new articles are posted on . Reducing steroids in favor of more targeted therapies can minimize organ damage in pediatric systemic lupus ...

In this retrospective analysis, responses persisted with hydroxychloroquine treatment. Results of a study suggest treatment using hydroxychloroquine (HCQ) for immune thrombocytopenia (ITP) related to ...

Please provide your email address to receive an email when new articles are posted on . Patients with pediatric lupus demonstrate better outcomes when all quality metrics are met. Researchers noted ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...

The 200-mg subcutaneous injection is for children 5 years and older. HealthDay News — The US Food and Drug Administration has approved a 200 mg subcutaneous route of administration of Benlysta ...